What is Tevogen Bio's earnings per share (EPS)?

Tevogen Bio (TVGN) reported diluted earnings per share of $-8.08 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Tevogen Bio Financials

TVGN

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Tevogen Bio (TVGN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI TVGN FY2025 2026-04-30

Tevogen Bio’s dominant operating mechanic is an externally funded cash burn, with little sign that spending is building fixed assets.

In FY2025, free cash flow of -$12.4M was nearly the same as operating cash flow of -$12.3M because capital spending was only $64K; matched against $11.7M of financing inflow, that means new capital is mainly covering operating use of cash rather than creating a larger asset base. The same pattern was visible in FY2024, so this looks like a recurring funding structure, not a one-off reset.

The balance sheet changed shape sharply after FY2023: total liabilities fell from $99.9M to $12.6M by FY2025, and negative equity narrowed from -$94.4M to -$8.2M. But liquidity remained tight because the current ratio was only 0.2x and cash was $0, so the cleanup did not translate into much day-to-day funding cushion.

FY2025 spending was not primarily a facilities build-out: SG&A at $15.0M exceeded R&D at $11.1M, while capex stayed negligible. With no reported revenue in these annual figures, that suggests cash use is being absorbed by organizational and public-company costs alongside research, not by asset-heavy expansion.

Financial Health Signals

Financial Profile 0/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Tevogen Bio's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Liquidity

Tevogen Bio's current ratio of 0.22 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

N/A

EPS (Diluted)

$-8.08

Tevogen Bio earned $-8.08 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 130.9% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$12.4M

Tevogen Bio generated -$12.4M in free cash flow in fiscal year 2025, representing cash available after capex.

Cash & Debt

Tevogen Bio held $0 in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

Tevogen Bio had 4M shares outstanding in fiscal year 2025. This represents a decrease of 97.7% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$11.1M

Tevogen Bio invested $11.1M in research and development in fiscal year 2025.

Share Buybacks

N/A

Capital Expenditures

$64K

Tevogen Bio invested $64K in capex in fiscal year 2025, funding long-term assets and infrastructure.

TVGN Income Statement

Metric	FY25	FY24	FY23	FY22
Revenue	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A
R&D Expenses	$11.1M	N/A	$4.4M	N/A
SG&A Expenses	$15.0M	N/A	$4.4M+365.8%	$953K
Operating Income	N/A	N/A	-$8.8M	N/A
Interest Expense	-$196K-206.3%	$184K-84.7%	$1.2M	N/A
Income Tax	$5K+171.4%	$2K	N/A	N/A
Net Income	N/A	-$13.7M	N/A	$4.4M
EPS (Diluted)	$-8.08	$-3.50-43.4%	$-2.44	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$3.1M	N/A	$3.1M+15.2%	$2.7M-15.5%	$3.2M	N/A	$3.3M-20.9%	$4.1M
SG&A Expenses	$2.3M	N/A	$2.6M-4.6%	$2.7M-61.7%	$7.2M	N/A	$2.8M-36.9%	$4.5M
Operating Income	-$5.4M	N/A	-$5.7M-5.2%	-$5.4M+47.4%	-$10.4M	N/A	-$6.1M+29.2%	-$8.6M
Interest Expense	-$71K	N/A	-$62K-63.9%	-$38K-254.8%	$25K	N/A	$12K+207550.0%	$6
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$5.4M	N/A	-$5.7M-4.0%	-$5.5M+46.9%	-$10.4M	N/A	-$5.9M+39.1%	-$9.7M
EPS (Diluted)	$-1.61	N/A	$-0.030.0%	$-0.03+99.1%	$-3.25	N/A	$-0.03+25.0%	$-0.04

TVGN Balance Sheet

Metric	FY25	FY24	FY23	FY22
Total Assets	$4.4M+26.6%	$3.5M-37.1%	$5.5M-98.5%	$357.1M
Current Assets	$1.5M-34.8%	$2.4M+37.0%	$1.7M+528.0%	$274K
Cash & Equivalents	$0	$0	$0-100.0%	$129K
Inventory	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A
Total Liabilities	$12.6M+24.5%	$10.1M-89.9%	$99.9M-74.4%	$391.1M
Current Liabilities	$7.1M-21.8%	$9.0M-89.4%	$85.5M+24291.1%	$350K
Long-Term Debt	N/A	N/A	N/A	N/A
Total Equity	-$8.2M-23.4%	-$6.7M+92.9%	-$94.4M-178.1%	-$34.0M
Retained Earnings	-$139.7M-23.2%	-$113.4M-13.8%	-$99.7M-574.1%	-$14.8M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$4.9M+12.3%	$4.4M-2.5%	$4.5M+5.3%	$4.3M+4.8%	$4.1M+17.7%	$3.5M-19.3%	$4.3M+29.6%	$3.3M
Current Assets	$2.1M+39.0%	$1.5M-27.4%	$2.1M+3.0%	$2.1M-33.0%	$3.1M+30.4%	$2.4M-33.1%	$3.5M+44.2%	$2.4M
Cash & Equivalents	$692K	$0-100.0%	$1.0M+51.3%	$685K-65.3%	$2.0M	$0-100.0%	$2.3M+105.3%	$1.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$14.8M+17.0%	$12.6M+2.4%	$12.3M-10.4%	$13.8M+16.6%	$11.8M+16.4%	$10.1M-3.3%	$10.5M-4.2%	$10.9M
Current Liabilities	$7.3M+2.8%	$7.1M+4.9%	$6.7M-16.6%	$8.1M-7.3%	$8.7M-3.6%	$9.0M-13.2%	$10.4M-1.8%	$10.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$9.8M-19.5%	-$8.2M-5.3%	-$7.8M+17.5%	-$9.5M-22.9%	-$7.7M-15.7%	-$6.7M-7.8%	-$6.2M+19.2%	-$7.7M
Retained Earnings	-$145.1M-3.9%	-$139.7M-3.5%	-$135.0M-4.4%	-$129.3M-4.4%	-$123.8M-9.1%	-$113.4M-9.1%	-$103.9M-6.0%	-$98.1M

TVGN Cash Flow Statement

Metric	FY25	FY24	FY23	FY22
Operating Cash Flow	-$12.3M-2.7%	-$12.0M-46.8%	-$8.2M-3693.6%	-$215K
Capital Expenditures	$64K	N/A	$133K	N/A
Free Cash Flow	-$12.4M	N/A	-$8.3M	N/A
Investing Cash Flow	-$64K	N/A	-$133K	N/A
Financing Cash Flow	$11.7M-4.6%	$12.2M+215.8%	$3.9M	N/A
Dividends Paid	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$2.7M-25.3%	-$2.2M+40.2%	-$3.6M-14.4%	-$3.2M+3.6%	-$3.3M-8.5%	-$3.0M+19.9%	-$3.8M-27.6%	-$3.0M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$2.9M+63.2%	$1.8M-56.0%	$4.0M+110.6%	$1.9M-52.5%	$4.0M+100.0%	$2.0M-60.0%	$5.0M+78.6%	$2.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

TVGN Financial Ratios

Metric	FY25	FY24	FY23	FY22
Gross Margin	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A
Return on Assets	N/A	-396.6%	N/A	1.2%
Current Ratio	0.22-0.0	0.26+0.2	0.02-0.8	0.78
Debt-to-Equity	-1.53-0.0	-1.52-0.5	-1.06+10.5	-11.52
FCF Margin	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-110.7%	N/A	-127.4%+1.5pp	-128.9%+125.6pp	-254.5%	N/A	-137.2%+154.7pp	-291.9%
Current Ratio	0.29+0.1	0.22-0.1	0.31+0.1	0.26-0.1	0.35+0.1	0.26-0.1	0.34+0.1	0.23
Debt-to-Equity	-1.50+0.0	-1.53+0.0	-1.57-0.1	-1.45+0.1	-1.530.0	-1.52+0.2	-1.69-0.3	-1.43
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$8.2M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.22), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Kyverna Therapeutics KYTX

$541.1M

Innate Pharma Sa IPHA

$185.0M

NeOnc Technologies Holdings Inc NTHI

$139.4M

Caribou Biosciences, Inc. CRBU

$197.4M

Ventyx Biosciences, Inc. VTYX

$1.0B

Frequently Asked Questions

What is Tevogen Bio's free cash flow?

Tevogen Bio (TVGN) generated -$12.4M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Tevogen Bio's operating cash flow?

Tevogen Bio (TVGN) generated -$12.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Tevogen Bio's total assets?

Tevogen Bio (TVGN) had $4.4M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Tevogen Bio's capital expenditures?

Tevogen Bio (TVGN) invested $64K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Tevogen Bio spend on research and development?

Tevogen Bio (TVGN) invested $11.1M in research and development during fiscal year 2025.

How many shares does Tevogen Bio have outstanding?

Tevogen Bio (TVGN) had 4M shares outstanding as of fiscal year 2025.

What is Tevogen Bio's current ratio?

Tevogen Bio (TVGN) had a current ratio of 0.22 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Tevogen Bio's debt-to-equity ratio?

Tevogen Bio (TVGN) had a debt-to-equity ratio of -1.53 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Tevogen Bio's cash runway?

Based on fiscal year 2025 data, Tevogen Bio (TVGN) had $0 in cash against an annual operating cash burn of $12.3M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Tevogen Bio's debt-to-equity ratio negative or unusual?

Tevogen Bio (TVGN) has negative shareholder equity of -$8.2M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

How financially healthy is Tevogen Bio?

Tevogen Bio (TVGN) scores 0 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.